FIELD: medicine, obstetrics and gynecology.
SUBSTANCE: invention can be used to predict the development of hypertensive disorders during pregnancy. Among pregnant women who have undergone combined screening of the 1st trimester, pregnant women with a risk level of hypertensive disorders in the range of 1:101–1:250, calculated by Astraia program, are identified, and in this group, the risk of hypertensive disorders is additionally specified using PIHDP, the predictive index of hypertensive disorders of pregnancy calculated according to a given formula. With the value of PIHDP≥0.5 the risk is high, with the value of PIHDP<0.5 the risk is low.
EFFECT: method allows to prescribe prophylactic treatment and reduce the risk of further development of hypertensive disorders during pregnancy by clarifying the risk after the combined screening of the 1st trimester by assessing the totality of the most significant indicators.
1 cl, 2 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF RISK OF DEVELOPING PREECLAMPSIA | 2023 |
|
RU2817206C1 |
| METHOD FOR PREDICTION OF SEVERE PREECLAMPSIA | 2020 |
|
RU2739694C1 |
| PREDICTION OF PLACENTAL PREECLAMPSIA ACCORDING TO PLACENTOMETRY AT GESTATION 19-21 WEEKS IN LOW-RISK PATIENTS | 2021 |
|
RU2771762C1 |
| METHOD FOR PREDICTING EARLY PREECLAMPSIA ACCORDING TO THE LEVEL OF PROCOAGULANT ACTIVITY OF TISSUE FACTOR IN BLOOD PLASMA AT 19-21 WEEKS OF GESTATION IN PATIENTS OF THE LOW-RISK GROUP | 2022 |
|
RU2795083C1 |
| METHOD FOR PREDICTING EARLY FETAL GROWTH RETARDATION ACCORDING TO PLACENTOMETRY AT 19-21 WEEKS OF GESTATION IN LOW-RISK PATIENTS | 2022 |
|
RU2795084C1 |
| PREDICTION OF PREECLAMPSIA BASED ON DETERMINING EXTRACELLULAR FETAL DNA IN MATERNAL BLOOD WHEN SCREENING THE FIRST TRIMESTER OF PREGNANCY | 2019 |
|
RU2697845C1 |
| METHOD FOR FORMING RISK GROUP OF PRE-ECLAMPSIA | 2021 |
|
RU2762204C1 |
| METHOD OF PREDICTING THE RISK OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH TYPE 2 DIABETES MELLITUS | 2022 |
|
RU2800716C1 |
| METHOD OF PREDICTING THE RECURRENCE OF EARLY SEVERE PREECLAMPSIA BASED ON THE RESULTS OF A STUDY OF THE LEVEL OF PLACENTAL MICROVESICLES IN BLOOD PLASMA IN PATIENTS WITH SEVERE PREECLAMPSIA IN A PERSONAL HISTORY | 2022 |
|
RU2798715C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING PREECLAMPSIA (PE) IN FIRST TRIMESTER OF PREGNANCY | 2024 |
|
RU2821130C1 |
